Larsen B A, Alderdice C A, Hawkins D, Martin J R, Mitchell D M, Sheridan D P
Immunology Laboratory, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada.
J Rheumatol. 1989 Apr;16(4):455-8.
In a study of HLA-DR phenotypes in patients with rheumatoid arthritis (RA) and controls from the Saskatoon area and in Newfoundland, we found that certain phenotypes occurred more frequently in the patients than in healthy controls in both populations ("increased risk phenotypes"). The reverse was also true: certain phenotypes were reduced or excluded from patients with RA compared with controls. Three increased risk phenotypes with twice the expected frequencies or more were HLA-DR1,DR4; DR4 and DR4,DR5. Four "protective" phenotypes with half or less the expected frequencies were HLA-DR1, DR5; DR2; DR2,DR3 and DR3,DR7. We speculate that at least for the DR3,DR7 phenotype, the protective effect may be due to a hybrid DQw2 molecule.
在一项针对萨斯卡通地区和纽芬兰类风湿性关节炎(RA)患者及对照的HLA - DR表型研究中,我们发现某些表型在两组人群的患者中出现的频率均高于健康对照(“高风险表型”)。反之亦然:与对照相比,某些表型在RA患者中减少或不存在。预期频率两倍及以上的三种高风险表型为HLA - DR1、DR4;DR4和DR4、DR5。预期频率一半及以下的四种“保护性”表型为HLA - DR1、DR5;DR2;DR2、DR3和DR3、DR7。我们推测,至少对于DR3、DR7表型,其保护作用可能归因于一种混合的DQw2分子。